Efficacy of Carfilzomib (K), Pomalidomide (P), and Dexamethasone (d) in Heavily Pretreated Patients with Relapsed/ Refractory Multiple Myeloma (RRMM) in a Real World Setting

被引：5
|
作者：
Hobbs, Miriam [1 ]
Paludo, Jonas [1 ]
Fonder, Amie [1 ]
Abeykoon, Jithma P. [2 ]
Gertz, Morie A. [1 ]
Rajkumar, S. Vincent [1 ]
Go, Ronald S. [1 ]
Buadi, Francis K. [1 ]
Lacy, Martha Q. [1 ]
Leung, Nelson [1 ]
Dispenzieri, Angela [1 ]
Gonsalves, Wilson I. [1 ]
Dingli, David [1 ]
Hwa, Yi L. [1 ]
Kourelis, Taxiarchis [1 ]
Kyle, Robert A. [1 ]
Kumar, Shaji [1 ]
Kapoor, Prashant [1 ]
机构：
[1] Mayo Clin, Div Hematol, Rochester, MN USA
[2] Mayo Clin, Dept Internal Med, Rochester, MN USA
来源：
BLOOD | 2016年 / 128卷 / 22期
关键词：
D O I：
10.1182/blood.V128.22.3337.3337
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3337
引用
收藏
页数：6
相关论文
共 50 条
  • [21] Carfilzomib-Pomalidomide-Dexamethasone (KPD) in Relapsed/Refractory Multiple Myeloma Patients - an Institutional Retrospective Analysis
    Mehta, Pallavi
    Yadav, Neha
    Bhaarat, Mohan
    Mirgh, Sumeet Prakash
    Khushoo, Vishvdeep
    Thekuddan, Shinto Francis
    Agrawal, Narendra
    Ahmed, Rayaz
    Bhurani, Dinesh
    BLOOD, 2019, 134
  • [22] Safety and efficacy of pomalidomide (POM), dexamethasone (DEX), and pegylated liposomal doxorubicin (PLD) for patients with relapsed/refractory multiple myeloma (RRMM).
    Berenson, James R.
    Stampleman, Laura
    Bessudo, Alberto
    Rosen, Peter
    Klein, Leonard M.
    Woliver, Thomas B. S.
    Flam, Marshall S.
    Eshaghian, Shahrooz
    Nassir, Youram
    Swift, Regina A.
    Vescio, Robert A.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [23] Oprozomib, pomalidomide, and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma
    Shah, Jatin
    Usmani, Saad
    Stadtmauer, Edward A.
    Rifkin, Robert M.
    Berenson, James R.
    Berdeja, Jesus G.
    Lyons, Roger M.
    Klippel, Zandra
    Chang, Yu-Lin
    Niesvizky, Ruben
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (09): : 570 - +
  • [24] Efficacy of Daratumumab, Pomalidomide and Dexamethasone Compared to Daratumumab, Carfilzomib and Dexamethasone in High Risk Relapsed Multiple Myeloma: Multicenter Real-World Experience
    Magee, Gray
    Mansour, Razan
    Chang, Mark
    Atrash, Shebli
    Ahmed, Nausheen
    Mushtaq, Muhammad Umair
    Ouchveridze, Evguenia
    Abdallah, Al-Ola
    Paul, Barry
    Green, Kimberly M.
    Davis, James A.
    Hashmi, Hamza
    BLOOD, 2024, 144 : 7034 - 7035
  • [25] POMALIDOMIDE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) PREVIOUSLY TREATED WITH LENALIDOMIDE
    Gomez, Hernando Marta
    Gironella, Merce
    Abella, Eugenia
    Cabezudo, Elena
    Motllo, Cristina
    Garcia, Antoni
    Sarra, Josep
    Mostacedo, Silvia
    Granell, Miquel
    Rosinol, Laura
    HAEMATOLOGICA, 2020, 105 : 13 - 14
  • [26] Melflufen Therapy for Relapsed Refractory Multiple Myeloma (RRMM) Patients Refractory to Daratumumab and/or Pomalidomide: A Report on Early Efficacy
    Mateos, Maria-Victoria
    Blade, Joan
    Larocca, Alessandra
    Oriol, Albert
    Rodriguez, Paula
    Alegre, Adrian
    Cavo, Michele
    Moreb, Jan S.
    Paner, Agne
    Gabrail, Nashat
    Halka, Kathleen G.
    Hassoun, Hani
    Maisel, Christopher
    Mazumder, Amitabha
    Zonder, Jeffrey A.
    Ocio, Enrique M.
    Byrne, Catriona
    Harmenberg, Johan
    Thuresson, Sara
    Nordstrom, Eva
    Lindberg, Jakob
    Richardson, Paul G.
    BLOOD, 2017, 130
  • [27] Carfilzomib, Pomalidomide, Dexamethasone with and without Daratumumab in Relapsed/Refractory Multiple Myeloma: A Multi-Center, Prospective Real World Study in China
    Zhang, Fujing
    Wang, Wei
    Wang, Hua
    Wang, Wei
    Liu, Aijun
    Tian, Weiwei
    Qin, Xiaoqi
    Xia, Zhongjun
    Zhuang, Junling
    BLOOD, 2024, 144 : 6985 - 6986
  • [28] The Real-World Outcomes of Relapsed/Refractory Multiple Myeloma Treated with Elotuzumab, Pomalidomide, and Dexamethasone
    Nakayama, Hitomi
    Aisa, Yoshinobu
    Ito, Chisako
    Sakurai, Aki
    Nakazato, Tomonori
    HEMATOLOGY REPORTS, 2024, 16 (04) : 593 - 602
  • [29] Clinical Efficacy of Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients
    De Novellis, Danilo
    Derudas, Daniele
    Vincelli, Donatella
    Fontana, Raffaele
    Della Pepa, Roberta
    Palmieri, Salvatore
    Accardi, Fabrizio
    Rotondo, Francesco
    Morelli, Emanuela
    Gigliotta, Emilia
    Roccotelli, Daniela
    Marano, Luana
    Barone, Maria Lucia
    Cetani, Giusy
    Esposito, Daniela
    Lazzaro, Antonio
    Delle Cave, Giuseppe
    Serio, Bianca
    Morini, Denise
    Porrazzo, Marika
    Urciuoli, Eleonora
    Masucci, Chiara
    Fanelli, Fulvia
    Rizzo, Michela
    Arcamone, Manuela
    Trastulli, Fabio
    Rocco, Stefano
    Leone, Aldo
    Bianco, Rosario
    Salvatore, Flavia
    Idato, Aurora
    Sicari, Maria
    Tosi, Patrizia
    Rascato, Maria Gabriella
    Di Perna, Maria
    Falcone, Antonietta Pia
    Morello, Lucia
    Carlisi, Melania
    Svanera, Gino
    Annunziata, Mario
    Frigeri, Ferdinando
    Califano, Catello
    Carella, Angelo Michele
    Marcacci, Gianpaolo
    Pane, Fabrizio
    Risitano, Antonio Maria
    Giudice, Valentina
    Botta, Ciro
    Selleri, Carmine
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2025, 114 (01) : 105 - 114
  • [30] Phase 1/2 study of carfilzomib, pomalidomide, and dexamethasone (KPd) in patients (Pts) with relapsed/refractory multiple myeloma (RRMM): A Multiple Myeloma Research Consortium multicenter study.
    Rosenbaum, Cara Ann
    Stephens, Leonor Ano
    Kukreti, Vishal
    Zonder, Jeffrey A.
    Cole, Craig
    Zimmerman, Todd M.
    Reece, Donna Ellen
    Berdeja, Jesus G.
    Severson, Erica
    Revethis, Andrea
    Wolfe, Brittany
    McDonnell, Kathryn
    Nam, Jennifer
    Griffith, Kent A.
    Jakubowiak, Andrzej J.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345